{"id":63565,"date":"2026-04-20T20:21:55","date_gmt":"2026-04-20T12:21:55","guid":{"rendered":"https:\/\/flcube.com\/?p=63565"},"modified":"2026-04-20T20:21:57","modified_gmt":"2026-04-20T12:21:57","slug":"pulnovo-medical-secures-100m-oversubscribed-financing-led-by-medtronic-padn-system-for-pulmonary-hypertension-attracts-global-investor-consortium","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63565","title":{"rendered":"Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic \u2013 PADN System for Pulmonary Hypertension Attracts Global Investor Consortium"},"content":{"rendered":"\n<p><strong>Pulnovo Medical<\/strong>, a Chinese <strong>pulmonary hypertension<\/strong> (PH) has secured <strong>over USD 100 million<\/strong> in an <strong>oversubscribed financing round<\/strong> led by <strong>Medtronic Inc.<\/strong> (NYSE: MDT), with continued participation from a prestigious investor consortium including <strong>EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, Lilly Asia Ventures<\/strong>, and <strong>Sequoia Capital China<\/strong>. The strategic investment coincides with a <strong>commercial partnership<\/strong> between Pulnovo and Medtronic to leverage the latter&#8217;s global commercialization infrastructure for widespread adoption of Pulnovo&#8217;s innovative <strong>pulmonary artery denervation<\/strong> (PADN).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-details\">Financing Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Investment Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Pulnovo Medical (Wuxi-based)<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Pulmonary hypertension (PH) medical devices<\/td><\/tr><tr><td><strong>Amount Raised<\/strong><\/td><td>USD 100+ million (oversubscribed)<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>Medtronic Inc. (NYSE: MDT)<\/td><\/tr><tr><td><strong>Existing Investors<\/strong><\/td><td>EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, Lilly Asia Ventures<\/td><\/tr><tr><td><strong>New Participants<\/strong><\/td><td>Sequoia Capital China, other global institutional investors<\/td><\/tr><tr><td><strong>Strategic Component<\/strong><\/td><td>Concurrent commercial partnership with Medtronic<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-clinical-innovation\">Technology Platform &amp; Clinical Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core Product:<\/strong> Pulmonary artery denervation (PADN) system<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Precisely targets core pathogenesis of cardiopulmonary diseases through catheter-based denervation<\/li>\n\n\n\n<li><strong>Clinical Benefits:<\/strong> Demonstrated significant improvements in functional capacity and patient outcomes<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Minimally invasive approach addressing underlying disease mechanisms rather than symptomatic management<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Independently developed by Pulnovo with proprietary technology platform<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-framework\">Strategic Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Partnership Element<\/th><th>Implementation<\/th><\/tr><\/thead><tbody><tr><td><strong>Commercial Synergies<\/strong><\/td><td>Leveraging complementary strengths in technology and market access<\/td><\/tr><tr><td><strong>Global Distribution<\/strong><\/td><td>Utilizing Medtronic&#8217;s established worldwide commercialization capabilities<\/td><\/tr><tr><td><strong>Market Penetration<\/strong><\/td><td>Joint promotion strategy for widespread application of PADN therapy<\/td><\/tr><tr><td><strong>Regulatory Strategy<\/strong><\/td><td>Coordinated approach to global regulatory approvals leveraging Medtronic&#8217;s experience<\/td><\/tr><tr><td><strong>Manufacturing Scale<\/strong><\/td><td>Potential integration with Medtronic&#8217;s manufacturing infrastructure for global supply<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investor-consortium-analysis\">Investor Consortium Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Corporate Investor:<\/strong> Medtronic brings not only capital but critical commercial infrastructure and global market access<\/li>\n\n\n\n<li><strong>Global Healthcare Specialists:<\/strong> EQT and OrbiMed provide international healthcare investment expertise and network effects<\/li>\n\n\n\n<li><strong>China-Focused VCs:<\/strong> Qiming, Gaorong, and Sequoia Capital China offer deep local market knowledge and ecosystem connections<\/li>\n\n\n\n<li><strong>Pharma-Adjacent Investment:<\/strong> Lilly Asia Ventures bridges pharmaceutical and device investment perspectives<\/li>\n\n\n\n<li><strong>Oversubscription Signal:<\/strong> Strong investor demand indicates high confidence in PADN technology and market opportunity<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Pulmonary Hypertension Prevalence<\/strong><\/td><td>Affects 15-50 million people globally; significant unmet medical need<\/td><\/tr><tr><td><strong>Current Treatment Limitations<\/strong><\/td><td>Existing therapies primarily address symptoms rather than underlying pathophysiology<\/td><\/tr><tr><td><strong>Interventional Market Gap<\/strong><\/td><td>Limited minimally invasive options for PH; PADN represents novel therapeutic approach<\/td><\/tr><tr><td><strong>Global Market Size<\/strong><\/td><td>PH therapeutics and devices market projected to exceed <strong>$8 billion by 2030<\/strong><\/td><\/tr><tr><td><strong>Competitive Differentiation<\/strong><\/td><td>PADN&#8217;s disease-modifying potential vs. purely symptomatic pharmacological approaches<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-implications-amp-global-expansion\">Commercial Implications &amp; Global Expansion<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Market Access:<\/strong> Medtronic partnership provides immediate access to established hospital relationships worldwide<\/li>\n\n\n\n<li><strong>Reimbursement Strategy:<\/strong> Leveraging Medtronic&#8217;s experience with interventional cardiovascular device reimbursement pathways<\/li>\n\n\n\n<li><strong>Clinical Evidence Generation:<\/strong> Joint investment in additional clinical trials to support global regulatory submissions<\/li>\n\n\n\n<li><strong>Geographic Rollout:<\/strong> Phased launch strategy starting with key markets where both companies have strong presence<\/li>\n\n\n\n<li><strong>Revenue Model:<\/strong> Combination of device sales, procedural support, and potential outcome-based pricing models<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance-for-stakeholders\">Strategic Significance for Stakeholders<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Pulnovo:<\/strong> Validates technology platform, provides substantial capital for expansion, and secures world-class commercial partner<\/li>\n\n\n\n<li><strong>For Medtronic:<\/strong> Expands cardiovascular portfolio into high-growth PH segment with innovative interventional approach<\/li>\n\n\n\n<li><strong>For Investors:<\/strong> Exposure to breakthrough technology addressing large unmet need with clear commercialization pathway<\/li>\n\n\n\n<li><strong>For Patients:<\/strong> Accelerated access to potentially disease-modifying therapy through established global distribution channels<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial performance, regulatory pathways, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pulnovo Medical, a Chinese pulmonary hypertension (PH) has secured over USD 100 million in an&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63566,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,233,1031,1749],"class_list":["post-63565","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-medtronic","tag-nyse-mdt","tag-pulnovo-medical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic \u2013 PADN System for Pulmonary Hypertension Attracts Global Investor Consortium - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pulnovo Medical, a Chinese pulmonary hypertension (PH) has secured over USD 100 million in an oversubscribed financing round led by Medtronic Inc. (NYSE: MDT), with continued participation from a prestigious investor consortium including EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, Lilly Asia Ventures, and Sequoia Capital China. The strategic investment coincides with a commercial partnership between Pulnovo and Medtronic to leverage the latter&#039;s global commercialization infrastructure for widespread adoption of Pulnovo&#039;s innovative pulmonary artery denervation (PADN).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63565\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic \u2013 PADN System for Pulmonary Hypertension Attracts Global Investor Consortium\" \/>\n<meta property=\"og:description\" content=\"Pulnovo Medical, a Chinese pulmonary hypertension (PH) has secured over USD 100 million in an oversubscribed financing round led by Medtronic Inc. (NYSE: MDT), with continued participation from a prestigious investor consortium including EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, Lilly Asia Ventures, and Sequoia Capital China. The strategic investment coincides with a commercial partnership between Pulnovo and Medtronic to leverage the latter&#039;s global commercialization infrastructure for widespread adoption of Pulnovo&#039;s innovative pulmonary artery denervation (PADN).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63565\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T12:21:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-20T12:21:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2004.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63565#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63565\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic \u2013 PADN System for Pulmonary Hypertension Attracts Global Investor Consortium\",\"datePublished\":\"2026-04-20T12:21:55+00:00\",\"dateModified\":\"2026-04-20T12:21:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63565\"},\"wordCount\":580,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63565#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2004.webp\",\"keywords\":[\"Finance\",\"Medtronic\",\"NYSE: MDT\",\"Pulnovo Medical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63565#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63565\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63565\",\"name\":\"Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic \u2013 PADN System for Pulmonary Hypertension Attracts Global Investor Consortium - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63565#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63565#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2004.webp\",\"datePublished\":\"2026-04-20T12:21:55+00:00\",\"dateModified\":\"2026-04-20T12:21:57+00:00\",\"description\":\"Pulnovo Medical, a Chinese pulmonary hypertension (PH) has secured over USD 100 million in an oversubscribed financing round led by Medtronic Inc. (NYSE: MDT), with continued participation from a prestigious investor consortium including EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, Lilly Asia Ventures, and Sequoia Capital China. The strategic investment coincides with a commercial partnership between Pulnovo and Medtronic to leverage the latter's global commercialization infrastructure for widespread adoption of Pulnovo's innovative pulmonary artery denervation (PADN).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63565#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63565\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63565#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2004.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2004.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic \u2013 PADN System for Pulmonary Hypertension Attracts Global Investor Consortium\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63565#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic \u2013 PADN System for Pulmonary Hypertension Attracts Global Investor Consortium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic \u2013 PADN System for Pulmonary Hypertension Attracts Global Investor Consortium - Insight, China&#039;s Pharmaceutical Industry","description":"Pulnovo Medical, a Chinese pulmonary hypertension (PH) has secured over USD 100 million in an oversubscribed financing round led by Medtronic Inc. (NYSE: MDT), with continued participation from a prestigious investor consortium including EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, Lilly Asia Ventures, and Sequoia Capital China. The strategic investment coincides with a commercial partnership between Pulnovo and Medtronic to leverage the latter's global commercialization infrastructure for widespread adoption of Pulnovo's innovative pulmonary artery denervation (PADN).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63565","og_locale":"en_US","og_type":"article","og_title":"Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic \u2013 PADN System for Pulmonary Hypertension Attracts Global Investor Consortium","og_description":"Pulnovo Medical, a Chinese pulmonary hypertension (PH) has secured over USD 100 million in an oversubscribed financing round led by Medtronic Inc. (NYSE: MDT), with continued participation from a prestigious investor consortium including EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, Lilly Asia Ventures, and Sequoia Capital China. The strategic investment coincides with a commercial partnership between Pulnovo and Medtronic to leverage the latter's global commercialization infrastructure for widespread adoption of Pulnovo's innovative pulmonary artery denervation (PADN).","og_url":"https:\/\/flcube.com\/?p=63565","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-20T12:21:55+00:00","article_modified_time":"2026-04-20T12:21:57+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2004.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63565#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63565"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic \u2013 PADN System for Pulmonary Hypertension Attracts Global Investor Consortium","datePublished":"2026-04-20T12:21:55+00:00","dateModified":"2026-04-20T12:21:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63565"},"wordCount":580,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63565#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2004.webp","keywords":["Finance","Medtronic","NYSE: MDT","Pulnovo Medical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63565#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63565","url":"https:\/\/flcube.com\/?p=63565","name":"Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic \u2013 PADN System for Pulmonary Hypertension Attracts Global Investor Consortium - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63565#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63565#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2004.webp","datePublished":"2026-04-20T12:21:55+00:00","dateModified":"2026-04-20T12:21:57+00:00","description":"Pulnovo Medical, a Chinese pulmonary hypertension (PH) has secured over USD 100 million in an oversubscribed financing round led by Medtronic Inc. (NYSE: MDT), with continued participation from a prestigious investor consortium including EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, Lilly Asia Ventures, and Sequoia Capital China. The strategic investment coincides with a commercial partnership between Pulnovo and Medtronic to leverage the latter's global commercialization infrastructure for widespread adoption of Pulnovo's innovative pulmonary artery denervation (PADN).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63565#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63565"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63565#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2004.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2004.webp","width":1080,"height":608,"caption":"Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic \u2013 PADN System for Pulmonary Hypertension Attracts Global Investor Consortium"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63565#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic \u2013 PADN System for Pulmonary Hypertension Attracts Global Investor Consortium"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2004.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63565"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63565\/revisions"}],"predecessor-version":[{"id":63567,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63565\/revisions\/63567"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63566"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}